ReviewObstetrics and gynecology2026
Cardiovascular-Related Maternal Mortality.
Review in Obstetrics and gynecology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Cardiovascular disease (CVD) is the leading cause of pregnancy-related death in the United States and disproportionately affects Black women. In this review, we address the major contributors to cardiovascular-related maternal deaths, focusing on the importance of both prepregnancy and postpartum care. Risk factors such as hypertension, diabetes, dyslipidemia, and obesity contribute to cardiovascular risk during and after pregnancy. As prepregnancy optimization of these factors has been shown to mitigate this risk, we discuss evidence-based approaches to cardiovascular risk management in reproductive-aged women. Women with pre-existing CVD should undergo prepregnancy counseling and risk assessment using validated tools such as the modified World Health Organization 2.0 classification. We review common presenting symptoms of CVD in pregnancy, such as shortness of breath, and we discuss how tools such N-terminal pro-B-type natriuretic peptide testing can help distinguish dyspnea of pregnancy from symptoms of heart failure. We also review the evidence-based management of the leading causes of cardiovascular-related maternal deaths, including cardiomyopathy, myocardial infarction, and hypertensive disorders of pregnancy. Importantly, the implementation of standardized care, such as perinatal CVD risk assessment algorithms, and postpartum remote monitoring programs may improve disparities in cardiovascular risk assessment and diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.